Back to Search Start Over

FDA to Review Resubmitted Tenapanor NDA for Hyperphosphatemia in CKD

Authors :
Duffy, Steve
Ernst, Diana
Source :
MPR Monthly Prescribing Reference. May 18, 2023
Publication Year :
2023

Abstract

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for tenapanor (Xphozah[sup.®]) for the control of serum phosphate in adult patients with chronic [...]

Subjects

Subjects :
United States. Food and Drug Administration
Chronic kidney failure -- Drug therapy
Phosphates -- Product development
Health

Details

Language :
English
ISSN :
08830266
Database :
Gale General OneFile
Journal :
MPR Monthly Prescribing Reference
Publication Type :
Periodical
Accession number :
edsgcl.749720110

Tools

Authors Abstract Subjects Details